Современные подходы к лечению анемии у больных с онкогематологическими заболеваниями

1. Lopez Oliva MO, Del Castillo Caba D, Fernandez Fresnedo G. Managing anaemia in kidney transplant patients with chronic kidney disease. Nefrologia 2009; 29 (Suppl. 1): 25–30.
2. Гусева С.А., Гончаров Я.П. Анемии. Киев: Логос, 2004.
3. Бессмельцев С.С. Современные подходы к  лечению анемии у больных со злокачественными новообразованиями. Онкология. 2008; 10 (2): 275–83.
4. Бредер В.В. Рак и анемия: причины и следствия или взаимосвязанные заболевания? Материалы научно-практич. конф. «Проблемы анемий в клиническолй практике». М., 2005; 8–9.
5. Hurlstone DP. Iron-deficiency anemia complicating AL amyloidosis with recurrent small bowel pseudo-obstruction and hindgut sparing. J Gastroenterol Hepatol 2002; 17 (5): 623–4.
6. Сараева Н.О. Механизмы развития анемии при гемобластозах. Гематол. и трансфузиол. 2007; 1: 31–7.
7. Ludwig H, Van Belle S, Barret-Lee P et al. Chemotherapy-associated anemia in breast cancer patients: Prevalence and incidence from the European Cancer Anaemia Survey (ECAS). Eur J Cancer 2003; 1 (Suppl. 5): 285 (Abstr. 947).
8. Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома. Современный взгляд на проблему.  Алматы, 2007.
9. Borbenyi Z. Etiology and treatment of malignancy-assotiated anaemia. Magy Onkol 2001; 45: 437–41.
10. Groopman J, Itti L. Chemotherapy–induced anemia in adults: incidents and treatment. J Natl Cancer Inst 1999; 91: 1616–34.
11. Harrison LB, Shasha D, White C et al. Radiotherapy-associated anemia: The scope of the problem. Oncologist 2000; 5 (Suppl. 2): 1–7.
12. Dammacco F, Marschner N, Liberati AM. Eepoetin alfa improves hemoglobin levels and quality of life parameters in anemic patients with hematologic malignancies receiving chemotherapy: interim results from EPOLYM trial. Hematol J 2004; 5 (Suppl. 2): 177–8 (Abstract 515).
13. Birgagard G, Gascon P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European cancer anemia survival. Eur J Haematol 2006; 77: 378–86.
14. Zhonghua Xue. Study on serum erythropoietin levels in patients with hematologic malignancies. Ye Xue Za Zhi 2006; 27: 543–5.
15. Ludwig H, Fritz E, Kontzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693–9.
16. Ludwig H, Rai K, Blade J et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoietin treatment recommendations. Hematol J 2002; 3: 121–30.
17. Румянцев А.Г., Аграненко В.А. Клиническая трансфузиология. М., 1997: 214–39.
18. Barret-Lee PJ, Bailey NP, O'Brein MER et al. Large-scalr UK audit of blood transfusion reguirement and anemia in patients receiving cytotoxic chemotherapy. Br JCancer 2000; 82: 93–7.
19. Wilson J, Yao Gl, Raftery J et al A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia assotiated with cancer, esoecially that attributable to cancer treatment. Health Technol Assess 2007; 11(13): 176.
20. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40: 2201–16.
21. Douglas RJ, Somerfield MR, Hagerty KL et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008; 111 (1): 25–41.
22. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875–82.
23. Katodritou E, Dimopoulos MA, Zervas K, Terpos E. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma. Cancer Treat Rev 2009; 35 (8): 738–43.
24. Bohlius J. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005; 97: 489–98.
25. Antonadou D. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies: final results of a randomized phase III study. Eur J Cancer 2001; 37 (Suppl. 6): S144.
26. Acs G. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001; 61: 3561–5.
27. Barclay L, Martin BN. Erythropoiesis-Stimulating Agents May Not Be Safe for Cancer Patients. JAMA 2008; 299: 914–24.
28. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532–42.
29. Hasselbalch HC, Clausen NT, Jensen BA. Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin. Am J Hematol 2002; 70 (2): 92–9.
30. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004; 127 (4): 399–403.
31. Bouranteas KL. Recombinant human erythropoietin for the treatment of anemia in chronic myelogenous leukemia. Eur J Haematol 1997; 59: 323–5.
32. Cortes J, O'Brien S, Quintas A et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 2004; 100: 2396–402.
33. Абдулкадыров К.М., Бессмельцев С.С. Апластическая анемия М: Наука; С.-Петербург: "KN", 1995.
34. Rumiantsev AG, Morshchakova EF, Pavlov AD. Erythropoietin: biological properties, mechanisms of action and production, clinical application. Budapest, 2002.
35. Эритропоэтин. Биологические свойства и клиническое применение. Под ред. С.А.Гусевой и В.Г.Бебешко. Киев, 2005.
36. Жуков Н.В. Рекомбинантный эпоэтин-бета (рекормон): лечение анемии у онкологических больных. Фарматека. 2006; 18: 1–4.
37. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301–7.
38. Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (rhEPO/epoetin-alpha) therapy in cancer patients. Blood 1995; 85: 315–21.
39. Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 1995; 86: 4444–53.
40. Miller CB, Jones RJ, Piantadosi S et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 325: 1689–92.
41. Katodritou E, Speletas M, Zervas K et al. Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Lab Hematol 2006; 12: 47–54.
42. Ohio R, Balteari E, Buileslrero A et al. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. Acta Hematol 1993; 90: 58–64.
43. Gandey A, Barclay L, Nicole Br. Martin Erythropoiesis-Stimulating Agents May Not Be Safe for Cancer Patients. JAMA 2008; 299: 914–24.
44. Douglas D. Epoetin Beta Does Not Affect Survival in Metastatic Breast Cancer. J Clin Oncol 2008; 26: 592–8.
45. Zonder JA. Thrombotic complications of multiple myeloma. Hematology 2006 (American Society of Hematology Education Program Book. Orlando, Florida, December 9–12, 2006): 348–55.
46. Palumbo A, Gay F. How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematology 2009 (American Society of Hematology. Education Program Book, New Orleans, Luisiana, December 5–8, 2009): 566–77.

С.С.Бессмельцев, Н.А.Романенко, К.М.Абдулкадыров

Российский научно-исследовательский институт гематологии и трансфузиологии, Санкт-Петербург